HERON THERAPEUTICS, INC. /DE/ Number of Reportable Segments
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:NumberOfReportableSegments · last filed 2026-08-10
- HERON THERAPEUTICS, INC. /DE/ number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- HERON THERAPEUTICS, INC. /DE/ number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- HERON THERAPEUTICS, INC. /DE/ number of reportable segments for fiscal 2025 was 1.00 Segment, a 0.00% change from fiscal 2024.
- HERON THERAPEUTICS, INC. /DE/ number of reportable segments for fiscal 2024 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-08 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | 1.00 Segment 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |